...
首页> 外文期刊>Cytotherapy >Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up
【24h】

Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up

机译:自体骨髓源性造血干细胞移植治疗肌萎缩性侧索硬化症患者:1年随访

获取原文
获取原文并翻译 | 示例
           

摘要

Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive loss of spinal cord and cortical motoneurons. Despite improved understanding of the mechanisms underlying ALS, in clinical practice the management of ALS remains essentially supportive and focused on symptom relief. However, over the past few years stem cell research has expanded greatly as a tool for developing potential new therapies for treating incurable neurodegenerative diseases. Methods Thirteen patients with sporadic amyotrophic lateral sclerosis (SALS) were included in this study, and bone marrow (BM)-derived hematopoietic progenitor stem cells were used. We selected patients with bulbar involvement and severe loss of movement. Our aim was to put the stem cells into the end of the brain stem and at the beginning of the spinal cord because the blood-brain barrier is intact in ALS and this region was the most affected part in our patients. Under general anesthesia, a total laminectomy was performed at the C1-C2 level. Stem cells were injected to the anterior part of the spinal cord. Results During the follow-up of 1 year after stem cell implantation, nine patients became much better compared with their pre-operative status, confirmed by electro neuro myography (ENMG). One patient was stable without any decline or improvement in his status. Three patients died 1.5, 2 and 9 months, respectively, after stem cell therapy as a result of lung infection and myocardial infarction (MI). Discussion These results show that stem cell therapy is a safe, effective and promising treatment for ALS patients.
机译:背景肌萎缩性侧索硬化症(ALS)是一种致命的神经退行性疾病,其特征是脊髓和皮质运动神经元的逐渐丧失。尽管人们对ALS的基本机制有了更深入的了解,但在临床实践中,ALS的治疗本质上仍是支持性的,并集中于症状缓解。然而,在过去的几年中,干细胞的研究已经大大扩展,作为开发用于治疗不可治愈的神经退行性疾病的潜在新疗法的工具。方法纳入13例散发性肌萎缩性侧索硬化症(SALS)患者,并使用骨髓(BM)来源的造血祖细胞。我们选择了延髓受累且运动严重丧失的患者。我们的目标是将干细胞放入脑干的末端和脊髓的起点,因为ALS中的血脑屏障完好无损,并且该区域是我们患者中受影响最大的部分。在全身麻醉下,以C1-C2水平进行全椎板切除术。干细胞被注射到脊髓的前部。结果干细胞植入术后1年的随访中,有9例患者的电神经肌电图(ENMG)证实其术前状态好转。一名患者病情稳定,状态没有任何下降或改善。三例患者在干细胞治疗后因肺部感染和心肌梗死(MI)分别死亡1.5、2和9个月。讨论这些结果表明,干细胞疗法对于ALS患者是一种安全,有效和有前途的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号